Avadel Recognizes World Narcolepsy Day and Announces New Data Presentations from Pivotal Phase 3 REST-ON Trial of FT218 at Upcoming Conference - Seite 2

“For people living with narcolepsy, the unpredictability of their symptoms can leave them feeling ashamed, stigmatized socially and scared to engage in activities they enjoy,” said Dr. Akinyemi O. Ajayi, Sleep Specialist, Medical Director, Florida Pediatric Research Institute. “Compounding the problem is that narcolepsy is often undiagnosed or misdiagnosed, leaving those who suffer from it without any options to manage their symptoms. World Narcolepsy Day is a much needed awareness campaign to help educate the public of the burdensome symptoms of narcolepsy and the need for improved treatment options.”

“At Avadel, we have been longstanding supporters of the narcolepsy community and are proud to reinforce our unwavering commitment this World Narcolepsy Day by raising awareness and elevating patient challenges,” said Greg Divis, Chief Executive Officer of Avadel. “We understand that the relentless daytime and nighttime symptoms of narcolepsy have a significant impact on patients’ personal, professional and social lives. World Narcolepsy Day is a much needed public awareness campaign, helping to reduce stigma and increase visibility for those living with narcolepsy around the world.”

In addition to supporting World Narcolepsy Day, Avadel is also participating in upcoming patient and medical conferences, including:

• The annual Narcolepsy Network conference, taking place virtually October 2-3 where the Company is sponsoring a virtual exhibit booth and presenting patient and clinician perspectives on how to manage the disruption of narcolepsy.
• The American College of Chest Physicians annual meeting, taking place virtually October 17 - 20 where new data will be shared in three poster presentations.
• The annual meeting of the American Neurological Association), taking place virtually October 17 - 19 where encore posters featuring post hoc analyses from the REST-ON trial will be presented.
  

About FT218
FT218 is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.

In March 2020, Avadel completed the REST-ON study, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in adults with narcolepsy. Among the three co-primary endpoints, FT218 demonstrated statistically significant and clinically meaningful results in EDS, the clinician’s overall assessment of the patient’s functioning, and reduction in cataplexy attacks, for all three evaluated does when compared to placebo.